A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Study Number:EA6134
IRB Number:788089
Trial Type:Oncology - Melanoma & Skin
Trial Status:Open to Accrual
Date Posted:09/14/2015
Principal Investigator:Mei Tang, MD
Contact Name:Kathryn Tower
Phone:443-849-3285
Fax:(443) 849-3777
Description:

For more details on this study, please refer to the Clinicaltrials.gov website at the link below:

https://clinicaltrials.gov/ct2/show/NCT02224781?term=ea6134&rank=1

IMPORTANT Visitor Policy Changes

Recent Stories
|
Video
|
In the Media